Pesquisa de referências

Managing catastrophic medical claims -prescription drug trends

<?xml version="1.0" encoding="UTF-8"?><modsCollection xmlns="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-8.xsd">
<mods version="3.8">
<titleInfo>
<title>Managing catastrophic medical claims -prescription drug trends</title>
</titleInfo>
<name type="personal" usage="primary" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20190009331">
<namePart>Troutman, Mark</namePart>
<nameIdentifier>MAPA20190009331</nameIdentifier>
</name>
<name type="personal" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080195519">
<namePart>Jackson, Larry P.</namePart>
<nameIdentifier>MAPA20080195519</nameIdentifier>
</name>
<typeOfResource>text</typeOfResource>
<genre authority="marcgt">periodical</genre>
<originInfo>
<place>
<placeTerm type="code" authority="marccountry">usa</placeTerm>
</place>
<dateIssued encoding="marc">2019</dateIssued>
<issuance>serial</issuance>
</originInfo>
<language>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<form authority="marcform">print</form>
<extent>5 p. </extent>
</physicalDescription>
<abstract displayLabel="Summary">The major impact trend on catastrophic medical claims is specialty pharmacy developments in biosimilars, orphan drugs, and breakthrough therapies. This increasing pipeline of new specialty drugs and targeted therapies results from several market trends. Pharmaceutical manufacturers continue their direct-to-consumer advertising to increase consumer awareness. Increased utilization naturally occurs due to the aging population and trend toward outpatient health care, as well as new and more aggressive drug treatment plans. This situation creates a pushpull conflict between supplier and payer as suppliers push for solutions at highest cost to increase margin and payers push for solutions and lowest cost to increase bottom line.</abstract>
<note type="statement of responsibility"> Mark Troutman, Larry P. Jackson</note>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080567118">
<topic>Reclamaciones</topic>
</subject>
<subject xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MAPA20080606633">
<topic>Industria farmacéutica</topic>
</subject>
<classification authority="">7</classification>
<relatedItem type="host">
<titleInfo>
<title>Contingencies : American Academy of Actuaries</title>
</titleInfo>
<originInfo>
<publisher>Washington : American Academy of Actuaries, 2019-</publisher>
</originInfo>
<identifier type="local">MAP20190020794</identifier>
<part>
<text>07/01/2019 Año 2019 - January-February , p. 38-42</text>
</part>
</relatedItem>
<recordInfo>
<recordContentSource authority="marcorg">MAP</recordContentSource>
<recordCreationDate encoding="marc">190705</recordCreationDate>
<recordChangeDate encoding="iso8601">20190709110311.0</recordChangeDate>
<recordIdentifier source="MAP">MAP20190020879</recordIdentifier>
<languageOfCataloging>
<languageTerm type="code" authority="iso639-2b">spa</languageTerm>
</languageOfCataloging>
</recordInfo>
</mods>
</modsCollection>